Đang chuẩn bị liên kết để tải về tài liệu:
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been approved for treatment of metastatic melanomas with a BRAF p.V600E mutation. The clinical significance of non-codon 600 mutations remains unclear, in part, due to variation of kinase activity for different mutants. |